471 related articles for article (PubMed ID: 18938156)
1. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Day E; Waters B; Spiegel K; Alnadaf T; Manley PW; Buchdunger E; Walker C; Jarai G
Eur J Pharmacol; 2008 Dec; 599(1-3):44-53. PubMed ID: 18938156
[TBL] [Abstract][Full Text] [Related]
2. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
[TBL] [Abstract][Full Text] [Related]
3. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
Rix U; Remsing Rix LL; Terker AS; Fernbach NV; Hantschel O; Planyavsky M; Breitwieser FP; Herrmann H; Colinge J; Bennett KL; Augustin M; Till JH; Heinrich MC; Valent P; Superti-Furga G
Leukemia; 2010 Jan; 24(1):44-50. PubMed ID: 19890374
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2. Identification of collagen binding sites in DDR2.
Leitinger B
J Biol Chem; 2003 May; 278(19):16761-9. PubMed ID: 12611880
[TBL] [Abstract][Full Text] [Related]
6. Exploring the collagen-binding site of the DDR1 tyrosine kinase receptor.
Abdulhussein R; McFadden C; Fuentes-Prior P; Vogel WF
J Biol Chem; 2004 Jul; 279(30):31462-70. PubMed ID: 15136580
[TBL] [Abstract][Full Text] [Related]
7. Discoidin Domain Receptor 1 Inhibitors: Advances and Future Directions for Novel Therapeutics with Aid of DNA Encoded Library Screens and Artificial Intelligence.
Sanawar R; Sahayasheela VJ; Sarath P; Dan VM
Mini Rev Med Chem; 2023; 23(15):1507-1513. PubMed ID: 36698236
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Cellular and Molecular Mechanism of Discoidin Domain Receptors (DDR1 and DDR2) in Bone Formation, Regeneration, and Its Associated Disease Conditions.
Mariadoss AVA; Wang CZ
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834343
[TBL] [Abstract][Full Text] [Related]
9. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
[TBL] [Abstract][Full Text] [Related]
10. Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery.
Kothiwale S; Borza CM; Lowe EW; Pozzi A; Meiler J
Drug Discov Today; 2015 Feb; 20(2):255-61. PubMed ID: 25284748
[TBL] [Abstract][Full Text] [Related]
11. Therapy options in imatinib failures.
Ramirez P; DiPersio JF
Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
Gao M; Duan L; Luo J; Zhang L; Lu X; Zhang Y; Zhang Z; Tu Z; Xu Y; Ren X; Ding K
J Med Chem; 2013 Apr; 56(8):3281-95. PubMed ID: 23521020
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
O'Hare T; Walters DK; Stoffregen EP; Jia T; Manley PW; Mestan J; Cowan-Jacob SW; Lee FY; Heinrich MC; Deininger MW; Druker BJ
Cancer Res; 2005 Jun; 65(11):4500-5. PubMed ID: 15930265
[TBL] [Abstract][Full Text] [Related]
14. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Deguchi Y; Kimura S; Ashihara E; Niwa T; Hodohara K; Fujiyama Y; Maekawa T
Leuk Res; 2008 Jun; 32(6):980-3. PubMed ID: 18191450
[TBL] [Abstract][Full Text] [Related]
15. The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
Deadman BJ; Hopkin MD; Baxendale IR; Ley SV
Org Biomol Chem; 2013 Mar; 11(11):1766-800. PubMed ID: 23247657
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
Liu L; Hussain M; Luo J; Duan A; Chen C; Tu Z; Zhang J
Chem Biol Drug Des; 2017 Mar; 89(3):420-427. PubMed ID: 27589335
[TBL] [Abstract][Full Text] [Related]
17. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
[TBL] [Abstract][Full Text] [Related]
19. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
20. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
